Description
In vitro and in vivo studies will be conducted to further characterize OB-002.
Amendment chain · 7 entries
Each notch is one published row for this agreement: #0 is the original (placed at its start date) and each later notch is an amendment (placed at its amendment date). The height is the agreement's total value as of that row — the source column is cumulative, not a change amount — so the line reads as the commitment over time and the right-most notch is the current commitment shown in the header. For this agreement: $211,145 at start, $252,953 after amendment #6 (+$41,808).
- #02021-05-03$211,145
- #12022-01-28$211,145
- #22022-07-12$252,953+$41,808
- #32022-10-28$252,953
- #42023-03-13$252,953
- #52023-11-07$252,953
- #62024-03-12$252,953
| Row | Date | Total value as of row | Change vs previous | Description on this row |
|---|---|---|---|---|
| #0 original | 2021-05-03(start date) | $211,145 | — | In vitro and in vivo studies will be conducted to further characterize OB-002. |
| #1 amendment | 2022-01-28 | $211,145 | +$0 | In vitro and in vivo studies will be conducted to further characterize OB-002. |
| #2 amendment | 2022-07-12 | $252,953 | +$41,808 | In vitro and in vivo studies will be conducted to further characterize OB-002. |
| #3 amendment | 2022-10-28 | $252,953 | +$0 | In vitro and in vivo studies will be conducted to further characterize OB-002. |
| #4 amendment | 2023-03-13 | $252,953 | +$0 | In vitro and in vivo studies will be conducted to further characterize OB-002. |
| #5 amendment | 2023-11-07 | $252,953 | +$0 | In vitro and in vivo studies will be conducted to further characterize OB-002. |
| #6 amendment | 2024-03-12 | $252,953 | +$0 | In vitro and in vivo studies will be conducted to further characterize OB-002. |
Related records · 6
Records are related by an explicit link in the data, stated for each group below — never by text similarity. Values are each agreement's current commitment (latest amendment).
Other current agreements for the same recipient (business number 708721493)
| Ref | Department · program | Current value | FY |
|---|---|---|---|
| 172-2020-2021-Q2-953967 | National Research Council Canada | Conseil national de recherches Canada · Industrial Research Assistance Program – Contributions to Firms | $334,360 | FY2021 |
Other recipients funded under "Industrial Research Assistance Program – Contributions to Firms" by National Research Council Canada | Conseil national de recherches Canada (most recent first)
| Ref | Recipient | Fiscal year | Current value | FY |
|---|---|---|---|---|
| 172-2025-2026-Q2-1034675 | Mediphage Bioceuticals, Inc. | FY2027 | $63,380 | FY2027 |
| 172-2025-2026-Q3-1037522 | OBKIO INC. | FY2026 | $50,000 | FY2026 |
| 172-2025-2026-Q3-1037889 | SERVICES DE DEVELOPPEMENT PROFESSIONELS SDP INC | FY2026 | $25,000 | FY2026 |
| 172-2025-2026-Q2-1034040 | Griffith Foods Limited | FY2026 | $54,880 | FY2026 |
| 172-2025-2026-Q3-1037273 | Apollo Machine & Welding Ltd. | FY2026 | $230,000 | FY2026 |
Cite as: Glassbox record view · Federal grants & contributions · 172-2021-2022-Q3-978814 · retrieved 2026-11-15.